Neuroscience - 22 May 2019
ESOC_poster_2019: A Phase III, Prospective, Double-Blind, Randomized, Placebo-Controlled Trial to Assess the Efficacy and Safety of Tenecteplase in Imaging-Eligible, Late-Window Patients With Acute Ischemic Stroke (TIMELESS)
This Phase III, prospective, double-blind, randomized, placebo-controlled trial (NCT03785678) willevaluate the efficacy and safety of tenecteplase vs. placebo in patients with AIS who present in the 4.5- to 24-hour time window with an internal carotid artery (ICA) or middle cerebral artery (MCA; M1 or M2) occlusion and evidence of salvageable tissue onbaseline computed tomography (CT) or magnetic resonance imaging (MRI) scan.
Neuroscience - 17 May 2019
What is Huntington's disease?
Huntington’s disease is a genetic, neurodegenerative and ultimately fatal disease with devastating impact on individuals and entire families. Despite knowing the exact cause of Huntington’s disease since 1993, there still remains much unknown about this complex brain disease. In this animation, Lauren Byrne, a Research Fellow at the UCL Huntington's Disease Centre shares her personal experience with Huntington's. She takes us inside the brain to explore the mechanism of this disease leading to the cognitive, behavioural and motor symptoms in Huntington's.
Neuroscience - 15 May 2019
AAN Poster 2019: Preliminary reliability and validity of a novel digital biomarker smartphone application to assess cognitive and motor symptoms in Huntington’s disease (HD)
This study aimed to determine the relability and validity of a remote digital monitoring platform comprised of a smartphone application to measure cognitive and motor symptoms in patients with early manifest Huntington's disease.